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Measurement of circulating heparin concentration has been suggested to 
optimize anticoagulation during cardiopulmonary b pass. The Hepcon/HMS 
device (Medtronic HemoTec, Inc., Parker, Colo.) uses heparin/protamine 
titration to quantitatively determine heparin concentration. Extensive valida- 
tion of this instrument is still lacking. Methods: Agreement between heparin 
concentrations measured by the Hepcon/HMS system and by laboratory 
determination was evaluated in 16 patients undergoing cardiac operations. For 
laboratory determinations, plasma heparin concentration was derived from 
the measure of anti-Xa activity by means of a chromogenic substrate tech- 
nique. The Hepcon/HMS instrument and cartridges measured whole blood 
heparin concentration. Samples were analyzed 5minutes after administration 
of heparin, 15 and 30 minutes after the start of cardiopulmonary b pass, 5 
minutes after aortic unclamping, at the end of cardiopulmonary b pass, and 
after administration ofprotamine. Data were plotted and interpreted accord- 
ing to the method of Bland and Altman: First, a difference less than 1.4 U/ml 
(i.e., ---0.7 U/ml) was chosen as acceptable, because it would not cause major 
difficulties in clinical interpretation; second, the difference between the two 
measurement techniques was plotted against he mean of the two measures. 
Results: The mean difference (bias) between heparin concentrations derived by 
the Hepcon/HMS device and those obtained by laboratory determination was 
as expected for measures performed on whole blood versus plasma (1.45 U/ml). 
Nevertheless, heparin concentrations derived by the Hepcon/HMS device may 
be as much as 2.76 U/ml above or 6.17 U/ml below the concentrations measured 
in the laboratory, differences well outside the predetermined limits of agree- 
ment and clearly unacceptable for clinical purposes. Conclusion: We conclude 
that heparin concentrations determined with the Hepcon/HMS instrument do 
not agree with laboratory determination f heparin concentration. Monitoring 
of heparin concentrations during bypass with the Hepcon/HMS device cannot 
be recommended. (J Thorac Cardiovasc Surg 1996;112:154-61) 
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H eparin usually is administered according to a 
fixed dose regimen and anticoagulation is mon- 
itored with the activated coagulation time (ACT) 
during cardiopulmonary b pass (CPB). This method 
has several drawbacks: the individual response to 
heparin is notoriously variable and the ACT during 
CPB can be prolonged by depletion of coagulation 
factors, hypothermia, hemodilution, and platelet 
dysfunction. 1 It is thought hat inadequate monitor- 
ing of heparin effect can lead to subclinical coagu- 
lation, deplete clotting factors, and precipitate a 
post-CPB bleeding diathesis. Although the ACT 
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correlates well with heparin concentration before 
CPB, during CPB the ACT cannot be relied on to 
maintain an appropriate heparin concentration, as
determined by the ACT measured before CPB. 2 
Thus measurement of the circulating heparin con- 
centration has been suggested tooptimize anticoag- 
ulation during CPB. 2 
Plasma heparin concentration is determined in 
the hematology laboratory by means of an anti- 
factor Xa chromogenic substrate assay. 3 Purified 
antithrombin s added to the test plasma tobind all 
the heparin present i  the sample. Factor Xa (in 
excess) is neutralized by the heparin-antithrombin 
complex, and the remaining factor Xa hydrolyses a 
chromogenic substrate, liberating a chromophoric 
group that is read photometrically at a given wave- 
length. This method of determining heparin in 
plasma is not available to clinicians in real time 
because it requires pecialized equipment such as a 
photometer, centrifugation f each blood specimen, 
calibration of each new lot number of the heparin 
kit against a heparin standard of known concentra- 
tion, and performance of the actual assay by a 
qualified laboratory technologist. 
The Hepcon/HMS hemostasis management sys- 
tem (Medtronic HemoTec, Inc., Parker, Colo.) is a 
microprocessor-based, multichannel c ot-timing in- 
strument that uses the principle of heparin/prota- 
mine titration to quantitatively determine heparin 
concentration i  whole blood (Hepcon/HMS oper- 
ator's manual, Medtronic HemoTec, Inc., 1989). 
Contrary to the anti-factor Xa chromogenic sub- 
strate assay, the Hepcon HMS may be used at the 
patient's bedside. The device was designed (1) to 
evaluate, in vitro, the patient's response to heparin, 
(2) to calculate the dose of heparin required on the 
basis of the desired ACT, estimated blood volume, 
and extracorporeal circuit parameters, (3) to mea- 
sure the heparin concentration and calculate any 
additional heparin required to maintain the desired 
heparin concentration, and (4) to calculate the dose 
of protamine required to reverse heparin. Single-use 
multichannel test cartridges containing thrombo- 
plastin as the activator are inserted in the Hepcon/ 
HMS device, which will then deliver a predeter- 
mined volume of blood in each sampling chan- 
nel that contains a known concentration of prota- 
mine. The channel that neutralizes the heparin 
in the sample most closely will be the first to clot, 
as determined by an automated etection pro- 
cess. Eleven test cartridges are available to deter- 
mine heparin concentration, ranging between 0 and 
8.2 U/ml in increments of 0.4 (cartridge range 
between 0 and 1.2 U/ml) or 0.7 U/ml (all other 
cartridges; Heparin Assay Cartridges package in- 
sert, Medtronic HemoTec, Inc., 1992). 
Only one study has compared the Hepcon/HMS 
automated protamine titration method with a mea- 
surement of heparin concentration obtained by a 
standard laboratory assay. 2 Whole blood heparin 
concentration was found to correlate extremely well
with plasma heparin concentration, However, the 
correlation coefficient determines if two methods 
are related, not if they agree. 4 Agreement between 
two methods means that they can be used inter- 
changeably, which, in the present case, would be a 
major advantage in the clinical setting. Also, al- 
though the rationale for determining and maintain- 
ing the optimal heparin concentration during CPB is 
attractive, introduction of the Hepcon/HMS instru- 
ment into routine clinical practice requires extensive 
validation because of the initial cost of the device 
and, more important, of the single-use cartridges. 
The aim of the study was to evaluate the agree- 
ment between determinations of circulating heparin 
concentration with the Hepcon/HMS device and 
laboratory methods to confirm the (potential) use- 
fulness of the instrument under clinical conditions. 
Methods 
The study was approved by the Ethics Committee of the 
Montreal Heart Institute. Sixteen patients scheduled to 
undergo cardiac operations with extracorporeal circula- 
tion were studied. No attempt was made to standardize 
anesthetic, surgical, or perfusion techniques because, in 
actual practice, these may vary widely among profession- 
als. Although these practice variations may be expected to 
result in different heparin concentrations, they should not 
influence agreement between the two m thods of mea- 
surement. 
Blood specimens were obtained from a central venous 
catheter, after removal of at east three dead spaces, at the 
following time intervals: 5 minutes after the intraauricular 
injection of a 300 U/kg dose of pork mucosal heparin by 
the surgeon; 15and 30 minutes into CPB; 5 minutes after 
aortic unclamping; at theend of CPB; and 10 minutes 
after the administration of protamine. A completely filled 
3 ml Monoject syringe (Sherwood Medical, Inc., St. Louis, 
Mo.) was attached to a 19-gauge llA-inch blunt needle 
and inserted into the syringe holder of th  automated 
Hepcon/HMS sample dispenser. Another 4.5 ml of blood 
was transferred into a blue top Vacutainer tube (Becton 
Dickinson & Co., Rutherford, N.J.) containing 0.5 ml 
sodium citrate, mixed gently, and sent to th  hematology 
laboratory. 
A cartridge with the range estimated o be appropriate 
for the expected heparin concentration was inserted in the 
Hepcon/HMS device ahead of time, inasmuch as possible. 
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Fig. 1. Bland-Altman plot in view of determining agreement between laboratory anti-Xa determination f
plasma heparin concentration (plasma [Hep]) and whole blood determination of heparin concentration 
(whole blood [Hep]) with the Hepcon/HMS instrument. The shaded area shows the predetermined limits 
of agreement (-+0.7 U/ml, see text for details). 
This allowed it to stabilize at approximately 37 ° C, the 
heat block temperature of the instrument. When heparin 
concentration measured with the Hepcon/HMS device 
was at the limit of detection of any cartridge, this concen- 
tration was confirmed with the use of a cartridge with a 
more appropriate range. Only the results obtained from 
(or confirmed by) central channels are reported. 
On arrival at the hematology laboratory, the blood 
sample was centrifuged at 3500 rpm for 15 minutes. The 
decanted plasma was centrifuged for another 10 minutes 
and two aliquots were then frozen and stored at -70  ° C 
for later determination of heparin concentration. Plasma 
heparin concentration was derived from the measure of 
anti-factor Xa ctivity by means of a chromogenic sub- 
strate technique (Coatest heparin, Chromogenix A.B., 
M61ndal, Sweden). 3 For heparin concentrations above 0.7 
U/ml, samples were diluted as required with human 
normal plasma and the results multiplied by the appropri- 
ate dilution factor. 
Agreement between the two methods of measurement 
was established by analyzing the data according to the 
graphic method described by Bland and Altman. 4' s In 
summary, this statistical approach involves two major 
steps. 
Step 1. A decision must be made as to how large a 
difference between the two methods is permissible and 
will still support he conclusion that the two methods are 
interchangeable. Given heparin concentrations are ex- 
pected to range between 3 and 6 U/ml during CPB, and 
since the Hepcon/HMS device cannot discriminate be- 
tween heparin concentrations smaller than 0.7 U/ml, a 
difference less than 1.4 U/ml (or --0.7 U/ml) was arbi- 
trarily determined to be acceptable because it would not 
cause problems in clinical interpretation. 
Step 2. The difference between the two measurement 
techniques is plotted against he mean of the two mea- 
sures. The mean difference line (bias) and the lines 
representing two standard eviations on either side of the 
mean difference are plotted as well. The two measurement 
methods are judged to be interchangeable if the limits of 
agreement (_+2 standard eviations) do not exceed the 
chosen acceptable difference (step 1, represented as the 
shaded area in Fig. 1). Ideally, the bias hould be minimal. 
However, if there is a consistent bias, the operator of 
either device can adjust for the bias. The Bland-Altman 
analysis was repeated at each measurement interval. The 
results of these repeated analyses are summarized in Fig. 
2. 
Retrospectively, to allow comparisons with the study by 
Despotis and associates 2 and to help explain the bias 
between plasma and whole blood heparin concentration, 
we used hematocrit values to convert the latter into 
plasma-equivalent heparin concentrations u ing the stan- 
dard formula: Plasma-equivalent heparin concentration = 
(Whole blood heparin concentration x 100)/(100 - He- 
matocrit). 
Hematocrit value was obtained from arterial blood gas 
analysis with the Stat Profile 9 instrument (Nova Biomed- 
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Fig. 2. Mean difference (black circles) +_2 standard deviations (arrows) of the differences between 
laboratory anti-Xa determination of plasma heparin concentration (plasma [Hep]) and whole blood 
determination f heparin concentration with the Hepcon/HMS instrument (whole blood [Hep]) at different 
time intervals during the operation. Ao, Aortic. 
ical, Waltham, Mass.) determined at 30-minute intervals 
during CPB. Results of measurements made 5 minutes 
after injection of heparin were not converted because 
we could not determine retrospectively whether the 
patient was already supported by CPB at that time. The 
data were analyzed by the method of Bland and Alt- 
man 4 at each measurement interval. The results of 
these repeated analyses are presented in Fig. 3. Again, 
to allow comparisons, we calculated correlation coeffi- 
cients between plasma and whole blood heparin con- 
centration and between plasma and plasma-equivalent 
heparin concentration. 
Results 
Eighty-six pairs of measurements were available 
for final analysis. The correlation between plasma 
(laboratory) and whole blood (Hepcon/HMS de- 
vice) heparin concentration was highly significant 
(p < 0.0001), with an r -- 0.769. Fig. 1 shows the 
data plotted in accordance with the method of 
Bland and Altman. 4 The mean difference (bias) 
between plasma and whole blood determination 
of heparin concentration was 1.45 U/ml and the 
standard deviation of the differences was 1.65 U/ml. 
It was calculated that the limits of agreement for 95 % 
of all measurements ranged between 4.75 and -1.85 
U/ml. 
Fig. 2 plots the mean difference _+2 standard 
deviations between plasma and whole blood heparin 
concentration at each measurement interval. The 
bias ranged between 0.08 and 2.14 U/ml, and the 
standard deviations of the differences ranged be- 
tween 0.71 and 2.23 U/ml. Because the limits of 
agreement exceeded the chosen acceptable differ- 
ence of 1.4 U/ml, the two methods were judged not 
to be interchangeable. 
Hematocrit value was available for conversion of 
64 whole blood heparin concentrations into plasma- 
equivalent heparin concentrations. Fig. 3 shows the 
correlation for the 64 converted ata points. The 
correlation between plasma and plasma-equivalent 
heparin concentrations was highly statistically signif- 
icant (p < 0.0001), with an r = 0.791. 
The mean difference +2 standard eviations be- 
tween plasma and plasma-equivalent heparin con- 
centration at each measurement interval is presented 
in Fig. 4. The bias for the converted data r nged 
between 0.02 and 1.74 U/ml, and the standard evia- 
tion of the differences ranged between 0.79 and 1.73 
U/ml. Overall, for the 64 measurement pairs, the 
calculated bias and the standard deviation of the 
differences were 0.79 and 1.42 U/ml, respectively. 
The limits of agreement for 95% of all converted 
measurements ranged between 3.63 and -2.04 U/ml. 
Again, because the limits of agreement exceeded the 
chosen acceptable difference of 1.4 U/ml, the two 
methods were judged not to be interchangeable. 
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Fig. 3. Correlation between laboratory anti-Xa determination of plasma heparin concentration (plasma 
[Hep]) and plasma equivalent heparin concentration calculated from hematocrit value and whole blood 
determination ofheparin concentration with the Hepcon/HMS instrument (plas a quivalent [Hep]). 
Discuss ion  
The attributes of the ideal operating room mon- 
itor of anticoagulation i clude simplicity of opera- 
tion necessitating short operator attention, quickly 
available and reproducible results, minimal equip- 
ment using whole blood rather than plasma, and 
stable reagents. 6 The Hepcon/HMS device possesses 
several of the characteristics required, but whole 
blood heparin concentration may be as much as 2.76 
U/ml above or 6.17 U/ml below plasma heparin 
concentration measured in the hematology labora- 
tory (see Fig. 2). Overall, only 35% of measure- 
ments (30/86 data points) were within the predeter- 
mined limits of agreement (see Fig. 1, shaded area). 
These differences are clearly unacceptable for clin- 
ical purposes. 
Fig. 3 demonstrates two common errors in the 
medical iterature. First, the plot of the data shown 
in the figure helps gauge the degree of agreement 
between the two methods of measurement of hepa- 
tin concentration, but use of the correlation coeffi- 
cient is inappropriate in this case and would lead the 
unwary reader into thinking that the two methods 
are interchangeable. The nul hypothesis here is that 
the two methods are not linearly related and, as 
stated by Bland and Altman: "It would be amazing 
if two methods designed to measure the same 
quantity were not related."4 Moreover, alarge range 
of measures lends itself to high correlation coeffi- 
cients. 1 Inasmuch as investigators usually compare 
two methods over the whole range of values that 
may be encountered in clinical practice, a high 
correlation is almost certain. 4 Second, compari- 
son of measurement techniques by the use of repli- 
cate observations from one individual may falsely 
improve the estimate of precision owing to the 
elimination of interpatient variability (Reich DL, 
Newsletter of the Society of Cardiovascular Anes- 
thesiologists, April 1995, page 4). Thus, although 
more difficult to grasp as a whole, only the data 
presented in Figs. 2 and 4, summarizing the results 
of the Bland-Altman analyses obtained at each 
measurement interval, should be used to reach 
conclusions pertaining to the agreement between 
the two methods of measurement. 
Theoretically the two instruments hould agree, 
but a bias between whole blood and plasma heparin 
concentration is expected, because the same amount 
of heparin is diluted in a different volume. Predict- 
ably, whole blood heparin concentration underesti- 
mates plasma heparin concentration, and the mean 
bias between these two measures (1.45 U/ml) fell 
within the expected range of difference. Whole 
blood heparin concentration was retrospectively 
converted into plasma-equivalent heparin concen- 
tration to determine if bias and agreement could be 
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improved. Conversion corrected the bias in part but 
did not improve substantially the agreement be- 
tween the two methods. This conversion was retro- 
spective and may have been imperfect owing to 
suboptimal determination fhematocrit value, but it 
should be recalled that such a comparison was not 
the primary objective of our study. 
Both methods have been shown to be accurate. 
The performance characteristics of the Coatest hep- 
arin assay indicate a coefficient of variation between 
series of 2.6% and within series of 2.3% at the 0.7 
U/ml level (therapeutic levels in the medical con- 
text), and the assay allows detection of 0.05 U/ml of 
heparin (Coatest heparin package insert, Chro- 
mogenix A.B., 1992). Some variability in the results 
may be introduced by inaccurate blood sampling, 
plasma treatment, and dilution of the sample. How- 
ever, our personnel were highly trained and adhered 
scrupulously to the manufacturer's instructions. 
Similarly, a high degree of precision and accuracy 
was obtained with the Hepcon/HMS heparin assay 
cartridges in tests run on heparinized, recalcified 
plasma (Heparin Assay Cartridges package insert, 
Medtronic HemoTec, Inc., 1992). Yet a majority of 
cartridges allows detection of heparin concentration 
by only 0.7 U/ml increments. This represents an 
important and inherent variability of 15% or more, 
considering the heparin concentration usually at- 
tained during CPB (4 to 5 U/ml). Precision of the 
whole blood determination of heparin concentra- 
tion can probably be improved by using the mean of 
two simultaneous measures, as in the study by 
Despotis and associates, 2 but this practice is both 
uncommon and expensive. 
Given its similarity with an ACT (whole blood 
assay, addition of an activator, detection of clotting 
as the end point), it can be postulated that the 
Hepcon/HMS whole blood heparin assay is affected 
also by those factors affecting the ACT: for example, 
hemodilution, hypothermia, and platelet dysfunc- 
tion. In theory, all channels hould be affected in 
like manner and the end result should not be 
altered. However, contrary to that of the different 
ACT-measuring instruments available, the repro- 
ducibility of the heparin/protamine titration instru- 
ments has not been scrutinized closely under the 
clinical conditions of CPB, in tests run on whole 
blood. 1 The coefficients of variation of five clotting 
methods of heparin assay in plasma have been 
shown to range between 3% and 78%, depending on 
the method tested, the heparin concentration, and 
the normality/abnormality of the plasma sample. 7 If 
this variability of whole blood heparin/protamine 
titration methods in patients undergoing CPB is 
confirmed by future studies, such poor internal 
reproducibility could beone of the factors explain- 
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ing the lack of agreement observed between the two 
methods examined in the present study. 
From a fundamental point of view, two other 
differences, related to the use of whole blood rather 
than plasma, must be sought o explain the lack of 
agreement between the two methods. First, the 
effects of heparin on platelets may increase the 
variability of whole blood clotting assays. Many of 
these effects demonstrated in vitro occur abruptly 
and should be applicable to patients undergoing 
CPB. It is clear that heparin binds avidly to platelets 
and induces a platelet release r action. 1 Platelet 
inhibition (by prostacyclin) or platelet activation (by 
adenosine diphosphate) prolongs the ACT by 61% 
and 52%, respectively, in healthy donor blood con- 
taining heparin 2 U/ml. In blood taken from the 
CPB circuit of 10 patients undergoing cardiac oper- 
ations and containing, presumably, a higher heparin 
concentration, the ACT was prolonged indefinitely 
by addition of the platelet-inhibitor carbacyclin, a 
prostacyclin analog. 8Moreover, impairment of col- 
lagen-induced platelet aggregation is proportional 
to the dose of heparin administered during CPB in 
human beings. 9Thus the effect of heparin on plate- 
let function appears to vary with eparin concentra- 
tion. It remains uncertain whether the effects of 
heparin on platelet function are neutralized as rap- 
idly as those of circulating heparin. Consequently, it 
can be hypothesized that the lack of agreement 
between the plasma chromogenic assay and the 
Hepcon/HMS device may be explained by the con- 
founding effect of heparin concentration platelet 
function, an important component of the latter 
(clotting) assay. Also, inhibition of platelet activity 
by heparin/protamine complexes themselves ~°'a~ 
could alter the results of the clotting assay. 
Second, both techniques determine the concen- 
tration of active heparin molecules, but the methods 
used are different. Heparin activity depends on its 
dramatic acceleration of the effect of antithrombin 
III, a naturally occurring, slow-acting inhibitor of 
coagulation present in human blood. The concen- 
tration of antithrombin III present in the samples 
tested by the two methods varies considerably. For 
the plasma determination f heparin concentration, 
exogenous antithrombin III is added in excess to 
bind all the heparin molecules responsible for anti- 
coagulation. Consequently, the activated factor X 
method measures the optimal effect of all the active 
heparin molecules present in the sample. On the 
other hand, during CPB, blood fed into the Hepcon/ 
HMS analyzer contains antithrombin III concentra- 
tions that vary between 47% and 75% of normal 
values. 12-14 Theoretically, only the effect of those 
heparin molecules bound to antithrombin III and 
active in vivo are measured by the Hepcon/HMS 
device. Thus such differences in antithrombin III 
concentrations may certainly contribute to the lack 
of agreement observed between the two methods. 
The costs involved by the application of new 
technologies with respect to the expected benefits of 
their introduction must be xamined. The cost con- 
siderations for the purchase of instruments and 
disposables for automated tests are certainly among 
the factors that will affect he choice of a monitor of 
coagulation. 6 The issue of cost is a relative one, but 
it cannot be argued that the cost per patient of 
monitoring heparin concentration is much more 
than that associated with the ACT. Despite appeal- 
ing arguments in favor of monitoring heparin con- 
centration, a majority of articles published up to 
1993 did not demonstrate conclusively that such 
monitoring is responsible for decreased postopera- 
tive bleeding and use of allogeneic blood products. 1 
More recently, maintenance of a "therapeutic" hep- 
arin concentration a d determination f an appro- 
priate protamine dose have been shown to reduce 
blood product use in patients requiring CPB. 15 
Alternatively, the favorable outcome observed could 
result simply from the use of a larger dose of heparin 
and a reduced protamine dosage (inasmuch as the 
Hepcon/HMS device tends to underestimate plasma 
heparin concentration) and, largely, be independent of 
the device used to monitor heparin concentration. 
During the same period, several investigators 
demonstrated decreased allogeneic transfusions us- 
ing different, often less costly, methods--the admin- 
istration of heparin and protamine according to in 
vitro predictive tests integrating drugs, tests, and 
patient response (RxDx System, International Tech- 
nidyne Corporation, Edison, N.J.)16; the manage- 
ment of patients with a transfusion algorithm based 
on on-site coagulation data (platelet count, pro- 
thrombin time, and activated partial thromboplastin 
time)17; or the institution of a thromboelastographi- 
cally guided coagulation monitoring program in 
patients undergoing CPB. 18 Thus good results (i.e., 
the reduction of patient exposure to allogeneic 
blood products 19) can be achieved by a number of 
different approaches involving more or less sophis- 
ticated technology, the costs of which can vary 
considerably. 
In conclusion, this study was unable to confirm 
the agreement between the Hepcon/HMS device 
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and the laboratory determination f circulating hep- 
arin concentration i  patients undergoing CPB for 
cardiac surgical procedures. Use of the Hepcon/ 
HMS instrument to monitor heparin concentration 
during CPB cannot be recommended. The physician 
must remember that monitoring of heparin concen- 
tration is only a surrogate for monitoring of antico- 
agulation. Clinicians still need a monitor of (anti-) 
coagulation that is as simple as the ACT, that uses 
whole blood rather than plasma, and that is capable 
of producing as rapid but more informative results. 
We express our gratitude to the hematology laboratory 
personnel who performed the determinations of anti-Xa 
plasma heparin concentration andto Medtronic Hemo- 
Tec, Inc., which kindly provided the Hepcon/HMS instru- 
ment and cartridges for this trial. 
REFERENCES 
1. Gravlee GP. Anticoagulation for cardiopulmonary bypass. 
In: Gravlee GP, Davis RF, Utley JR, editors. Cardiopulmo- 
nary bypass: principles andpractice. Baltimore: Williams & 
Wilkins, 1993:340-80. 
2. Despotis GJ, Summerfield AL, Joist JH, Goodnough LT, 
Santoro SA, Spitznagel E, et al. Comparison of activated 
coagulation time and whole blood heparin measurements 
with laboratory plasma anti-Xa heparin concentration in 
patients having cardiac operations. J Thorac Cardiovasc Surg 
1994;108:1076-82. 
3. Teien AN, Lie M, Abildgaard U. Assay of heparin in plasma 
using a chromogenic substrate for activated factor X. Thromb 
Res 1976;8:413-6. 
4. Bland JM, Altman DG. Statistical methods for assessing 
agreement between two methods of clinical measurement. 
Lancet 1986;1:307-10. 
5. LaMantia KR, O'Connor T, Barash PG. Comparing methods 
of measurement: an alternative approach. Anesthesiology 
1990;72:781-3. 
6. Jobes DR, Schwartz AJ, Ellison N, Andrews R, Rutfini RA, 
Ruffini JJ. Monitoring heparin anticoagulation and its neu-
tralization. Ann Thorac Surg 1981;31:161-6. 
7. Teien AN, Lie M. Heparin assay in plasma: a comparison of 
five clotting methods. Thromb Res 1975;7:777-88. 
8. Moorehead MT, Westengard JC, Bull BS. Platelet involve- 
ment in the activated coagulation time of heparinized blood. 
Anesth Analg 1984;63:394-8. 
9. Gravlee GP, Rogers AT, Dudas LM, et al. Heparin manage- 
ment protocol for cardiopulmonary bypass influences post- 
operative heparin rebound b t not bleeding. Anesthesiology 
1992;76:393-401. 
10. Mammen EF, Koets MH, Washington BC, et al. Hemostasis 
changes during cardiopulmonary bypass urgery. Semin 
Thromb Hemost 1985;11:281-92. 
11. Ellison N, Edmunds LH, Colman RW. Platelet aggregation 
following heparin a d protamine administration. Anesthesi- 
ology 1978;48:65-8. 
12. Hashimoto K, Yamagishi M, Sasaki T, Nakano M, Kurosawa 
H. Heparin and antithrombin III levels during cardioputmo- 
nary bypass: correlation with subclinical plasma coagulation. 
Ann Thorac Surg 1994;58:799-805. 
13. Dietrich W, Spannagl M, Schramm W, Vogt W,Barankay A, 
Richter JA. The influence of preoperative anticoagulation on 
heparin response during cardiopulmonary bypass. J Thorac 
Cardiovasc Surg 1991;102:505-14. 
14. Tanaka K, Takao M, Yada I, Yuasa H, Kusagawa M, 
Deguchi K. Alterations in coagulation and fibrinolysis asso- 
ciated with cardiopulmonary bypass during open heart sur- 
gery. J Cardiothorac Anesth 1989;3:181-8. 
15. Despotis GJ, Joist JH, Hogue CW Jr, Alsoufiev A, Kater K, 
Goodnough LT, et al. The impact of heparin concentration 
and activated clotting time monitoring on blood conserva- 
tion: a prospective, randomized evaluation in p ie ts under- 
going cardiac operation. J Thorac Cardiovasc Surg 1995;110: 
46-54. 
16. Jobes DR, Aitken GL, Shaffer GW. Increased accuracy and 
precision of heparin and protamine dosing reduces blood loss 
and transfusion i  patients undergoing primary cardiac op- 
erations. J Thorac Cardiovasc Surg 1995;110:36-45. 
17. Despotis GJ, Grishaber JE, Goodnough LT. The effect of an 
intraoperative treatment algorithm on physicians' transfusion 
practice in cardiac surgery. Transfusion 1994;34:290-6. 
18. Spiess BD, Gillies BSA, Chandler W, Verrier E. Changes in 
transfusion therapy ndreexploration rate after institution of 
a blood management program in c rdiac surgical patients. J 
Cardiothorac Vasc Anesth 1995;9:168-73. 
19. Hardy JF, B61isle S. Natural and synthetic antifibrinolytics in 
adult cardiac surgery: fficacy, effectiveness and efficiency. 
Can J Anaesth 1994;41:1104-12. 
